Zhang Rubin, Florman Sandy, Devidoss Sharmila, Zarifian April, Killackey Mary, Paramesh Anil, Fonseca Vivian, Batuman Vecihi, Hamm L Lee, Slakey Douglas
Tulane Abdominal Transplant Institute, Tulane University Health Sciences Center, New Orleans, LA, USA.
Clin Transplant. 2007 Sep-Oct;21(5):583-9. doi: 10.1111/j.1399-0012.2007.00692.x.
Interleukin-2 receptor (IL2R) antibody has emerged as an attractive induction therapy for organ transplant. However, the long-term outcome of basiliximab induction in simultaneous pancreas and kidney (SPK) transplant remains speculative. We retrospectively analyzed the long-term survivals of 91 consecutive SPK recipients with basiliximab as induction, combination of steroid, tacrolimus (TAC) and mycophenolate acid (MFA)--either mycophenolate mofetil (MMF) or sodium mycophenolate (myfortic) as maintenance. At one, three, five, and seven-yr, the actual patient survival rate were 91.2%, 90.3%, 88.1%, and 88.2%, respectively; kidney graft survivals were 90.1%, 84.7%, 78.6%, and 70.6%, respectively; and pancreas graft survivals were 86.8%, 80.6%, 71.4%, and 58.8% respectively. There was a low incidence of rejection and CMV infection. Basiliximab induction with TAC, MFA, and steroid maintenance therapy can provide excellent long-term outcome for SPK recipients.
白细胞介素-2受体（IL2R）抗体已成为一种有吸引力的器官移植诱导疗法。然而，巴利昔单抗诱导在胰肾联合移植（SPK）中的长期结果仍具有推测性。我们回顾性分析了91例连续接受巴利昔单抗诱导、联合使用类固醇、他克莫司（TAC）和霉酚酸（MFA）（以霉酚酸酯（MMF）或霉酚酸钠（米芙）作为维持治疗）的SPK受者的长期生存率。在1年、3年、5年和7年时，实际患者生存率分别为91.2%、90.3%、88.1%和88.2%；肾移植存活率分别为90.1%、84.7%、78.6%和70.6%；胰腺移植存活率分别为86.8%、80.6%、71.4%和58.8%。排斥反应和巨细胞病毒感染的发生率较低。巴利昔单抗诱导联合TAC、MFA和类固醇维持治疗可为SPK受者提供出色的长期结果。
